Back to Newsroom

ProMIS Neurosciences Designates PMN350 its Second Lead Product for Development in Alzheimer’s Disease

TORONTO, Ontario and CAMBRIDGE, Massachusetts – May 24, 2017 – ProMIS Neurosciences, a company focused on discovery and development of precision treatments for neurodegenerative diseases, today announced that it has designated PMN350 – a monoclonal antibody (mAb) targeting toxic prion-like forms of amyloid-beta oligomers (AβO) – as the Company’s second lead product for Alzheimer’s disease (AD).

“We previously demonstrated that PMN310, our first lead product for development in Alzheimer’s disease, presents the optimal target profile of selectively binding prion-like forms of AβO, inhibiting both their propagation and neurotoxicity,” stated Dr. Neil Cashman, ProMIS Chief Scientific Officer. “We have now achieved a significant development milestone by demonstrating that PMN350, our second AD lead product directed against a different target on toxic AβO, also displays the optimal target product profile in both in vitro and in vivo tests.”